Comparing two drug combos for first-line metastatic colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether a combination of chemotherapy drugs (NALIRIFOX) plus targeted therapy works better than another standard combination (FOLFOX) plus targeted therapy for people with metastatic colorectal cancer who haven't had treatment yet. It aims to find a more effective first treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have colorectal cancer that has spread (metastatic) and cannot be removed with surgery.
- You have not received any cancer medication for your metastatic disease yet.
- If you had chemotherapy before surgery, your cancer must have come back more than 12 months after that treatment ended.
- You have at least one tumor that can be measured on scans.
- You are in good enough physical condition to be up and about (ECOG score 0 or 1).
- Your blood and organ function are within normal ranges.
- You do not have a specific gene profile (MSI-H or dMMR) that would make immunotherapy a better option.
- You are not allergic to any of the study drugs.
- You are not underweight (BMI below 18.5).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two standard chemotherapy combinations for people whose colorectal cancer has spread and cannot be removed with surgery. Depending on certain genetic markers, participants also receive either bevacizumab or cetuximab to help the treatment work better.
This study is testing a combination of drugs for colorectal cancer that has spread and hasn't responded to first-line treatment. It aims to see if these drugs can help control the cancer and improve outcomes for people in your situation.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination chemotherapy called NALIRIFOX as a second treatment for people with advanced high-grade neuroendocrine cancers. The goal is to see if it can help when the first treatment didn't work.
This trial tests a combination of two oral medications for people with advanced colorectal cancer who cannot tolerate stronger chemotherapy. The goal is to see if this gentler approach slows tumor growth and improves quality of life.
This trial tests a combination of four chemotherapy drugs (NALIRIFOX) as a first treatment for people with advanced appendix or small intestine cancer. It aims to see if this combination is safe and effective.
Hear when a new Metastatic Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.